Methods: 95 NSCLC patients were selected for this study; realtime PCR and FISH methods were used to identify EGFR mutation and EML4-ALK rearrangement mutation Results: 48/95 (50, 5%) of NSCLC patients have mutation in exon 19 and 21 of EGFR gene; 6/95 (6, 3%) of NSCLC patients have EML4-ALK rearrangement mutation.